A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 in Subjects With Pemphigus.
Latest Information Update: 12 Oct 2024
Price :
$35 *
At a glance
- Drugs B 007 (Primary)
- Indications Pemphigus
- Focus Therapeutic Use
- Sponsors Shanghai Jiaolian Drug Research and Development
- 19 Jul 2024 Status changed from not yet recruiting to recruiting.
- 17 Jun 2024 New trial record